Home   Site Map   About Roche   Contact Us   Help   
This is a alt text for OsteoporosisThis is a alt text for Osteoporosis
Clinical. Credible. Convenient.
Main Menu
Osteoporosis Home
News
Clinical Trials
Education
Publications
Resources
Meeting Calendar

Select a link below to view details.
Previous July 2008 Next
S M T W T F S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    
Tell us what you think »
Osteoporosis Publications

Display by:    Publication date     Author     Alphabetical by Publication Title  
  Steven T. Harris, William A. Blumentals and Paul D. Miller
infotrieve.gif Locked Content Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies
Current Medical Research and Opinion 2008 24(1): 237 - 245
 
  Delmas PD, Adami S, Strugala C
infotrieve.gif Locked Content Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration study.
Arthritis and Rheumatism. 2006 54(6): 1838 - 1846
 
  Reginster J-Y, Adami S, Lakatos P
infotrieve.gif Locked Content Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Ann Rheum Dis. 2006 65(): 654 - 661
 
  Reginster JY, Wilson KM, Dumont E
infotrieve.gif Locked Content Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
J Clin Endocrin Metab. 2005 90(9): 5018 - 5024
 
  Miller PD, McClung MR, Macovei L
infotrieve.gif Locked Content Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from MOBILE study.
J Bone Miner Res. 2005 20(8): 1315 - 1322
 
  Chesnut III CH, Skag A, Christiansen C
infotrieve.gif Locked Content Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
J Bone Miner Res. 2004 19(8): 1241 - 1249
 
  McClung M, Wasnich R, Recker R
infotrieve.gif Locked Content Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
J Bone Miner Res. 2004 19(1): 11 - 18
 
  Tanko LB, McClung MR, Schimmer RC
infotrieve.gif Locked Content The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
Bone 2003 32(): 421 - 426